Agomab Reports Positive Topline Data from STENOVA Study of Ontunisertib
Agomab reported positive topline data from its STENOVA open-label extension study of ontunisertib in patients with Fibrostenosing Crohn's Disease (FSCD). The study maintained a favorable safety and tolerability profile through up to 60 weeks of treatment. Patients experienced a low annualized FSCD-related event rate of